Gonadotropins (LH, FSH, hCG): the glycoprotein hormones that run human reproduction

Also known as: gonadotrophins · pituitary gonadotropins (LH, FSH) · chorionic gonadotropin (hCG) · glycoprotein hormone family (with TSH). Reads the axis: GnRH → pituitary → gonads.

1. What a gonadotropin actually is

Strip away the long name and a gonadotropin is simply a chemical message aimed at the gonads — the ovaries and testes. The body sends it from a control centre in the brain and it tells the reproductive organs what to do next: grow an egg, release it, make testosterone, hold a pregnancy. Three molecules carry that message. FSH³ grows follicles and supports sperm production; LH² triggers ovulation and drives the sex-hormone factories; and hCG⁴ appears only in pregnancy, where it impersonates LH to keep the early pregnancy supplied with progesterone.

What makes them a family is their shape. Each is a glycoprotein: a protein coated in branched sugar chains. And each is a heterodimer — two different protein chains held together, not fused. One chain, the alpha subunit, is identical across LH, FSH, hCG and even the thyroid hormone TSH. The other, the beta subunit, is unique to each hormone and is what gives it its identity and its target. Notably, the beta chains of LH and hCG are near-twins, which is exactly why hCG can borrow LH's receptor.

2. The HPG axis — a three-storey chain of command

Gonadotropins do not act alone; they are the middle link in a cascade called the hypothalamic-pituitary-gonadal (HPG) axis. It works like a chain of command with built-in feedback:

The same three hormones read out very differently in the two sexes. In men, LH drives the Leydig cells to make testosterone, while FSH supports the Sertoli cells that nurse sperm. In women the axis runs a monthly programme: FSH grows a follicle, the follicle makes estradiol, and a sharp LH surge ruptures the follicle to release the egg — ovulation — after which the leftover follicle becomes the progesterone-making corpus luteum. If a pregnancy begins, hCG from the young placenta steps in to keep that corpus luteum alive.

3. Structure & receptors — why the sugar matters

Because the alpha subunit is shared, the identity of a gonadotropin lives almost entirely in its beta subunit and in its glycosylation — the specific pattern of sugar chains hung on the protein. Those sugars are not decoration. They control how the molecule folds, how the two subunits stay married, how fast the kidney clears it from blood, and how strongly it grips its receptor. hCG's beta chain carries an extra sugar-rich C-terminal tail that dramatically lengthens its half-life — the molecular reason a pregnancy hormone lingers while a pituitary pulse does not.

On the target cell, gonadotropins act through two G-protein-coupled receptors with large horseshoe-shaped binding domains. LH and hCG share a single receptor, LHCGR; FSH has its own, FSHR⁶. Both switch on the same internal messenger, cyclic AMP, to relay the order inside the cell. Sharing a receptor is what lets a placental hormone (hCG) and a clinical hCG injection do LH's job.

4. The three gonadotropins at a glance

Every one of these is a heterodimer of the same alpha subunit plus its own beta subunit — a small molecular toolkit reused for very different jobs.

5. Why it matters — and the open frontier

Gonadotropins are not just physiology; they are medicine. Because they are the signal the gonads obey, giving them as drugs lets clinicians run the reproductive axis from outside. Purified and recombinant FSH and LH power controlled ovarian stimulation for IVF and ovulation induction; an hCG injection stands in for the natural LH surge to time the release of eggs. In men with hypogonadotropic hypogonadism — where the brain's signal is missing — gonadotropin therapy can restart testosterone and sperm production, something testosterone alone cannot do, since external testosterone actually silences the axis.

Here is the open problem. Gonadotropins are among the most awkward molecules in the pharmacy to keep intact. They are large, they are heavily glycosylated, and their two chains are held together only by weak non-covalent forces — pull the dimer apart and the hormone is dead. They cannot survive the gut, so every dose is an injection. They are prone to oxidation, aggregation and mechanical stress, and they lean on an unbroken cold chain from factory to clinic. This is the peptide-versus- glycoprotein delivery challenge in its sharpest form: the drug that solves infertility is the drug that most resents being dried, shipped and stored. Solving that last mile — making a fragile glycoprotein hormone as robust and as easy to handle as a simple small molecule — is one of the genuine frontiers of the field.

6. Panacea Bio Chem's line of work

Panacea Bio Chem researches exactly this frontier — the preservation and clean-delivery last mile for fragile glycoprotein hormones and peptides. The company's focus is not on redesigning the hormone but on protecting it: keeping the heterodimer folded and its two subunits married, shielding oxidation-prone residues, and carrying the molecule intact through the most destructive steps in its life, which are drying, storage and reconstitution. In practice that means treating a gonadotropin the way one treats any precious, easily-spoiled biologic — controlling every phase transition it passes through rather than masking the damage after the fact.

That work draws on the wider Panacea preservation stack: gentle low-temperature freeze-drying with Cryolapse, the gentle freeze-dry →; raising the glass-transition ceiling so an amorphous cake never softens with TgShift →; isolating a molecule from oxygen and trace metals in RedoxVault →; and shelf-free processing via LyoLevit →. The exact formulations, parameters and sequences Panacea uses to stabilise a given hormone remain proprietary — described here in outline, held in full behind the door.

7. Story — the fertility drug that came from urine

The most remarkable fact about gonadotropins is where the first fertility medicine actually came from. After menopause, a woman's pituitary — no longer reined in by the ovary — pours large amounts of FSH and LH into the blood, and the body sheds them in the urine. In 1950s Italy the researcher Piero Donini at Serono worked out how to extract usable gonadotropins from that urine, and the physician Bruno Lunenfeld⁷ turned the extract into a treatment. The result, menotropin — sold as Pergonal⁸ — needed the pooled urine of enormous numbers of postmenopausal women, famously collected across convents and retirement homes. Tens of thousands of litres of urine became the first babies conceived with medically induced ovulation. Only decades later did recombinant DNA let FSH and LH be brewed in cell culture, retiring the urine collection.

Gonadotropins have a second folk-legend too. Long before pregnancy sticks, the 1927 Aschheim-Zondek test⁹ detected pregnancy by injecting a woman's urine into an immature mouse: hCG in the urine would swell the animal's ovaries. It gave rise to the phrase "the rabbit died" — though the rabbit, used in a later variant, was always dissected, pregnant or not. Both stories share one thread: hCG and its cousins are so potent, and leave such a clear fingerprint, that biology could read them decades before chemistry could name them.

8. Where the impact could land

If the fragile-glycoprotein delivery problem yields, the highest-impact targets are the ones where cost, cold chain and self-injection hurt patients most:

• Home fertility care. IVF and ovulation-induction cycles ask patients to store and self-inject temperature-sensitive gonadotropins for days. A hormone that tolerates handling without a strict cold chain would lift a real burden and widen access.
• Single-vial, self-reconstituting doses. Pairing a stabilised gonadotropin cake with a cartridge that carries its own diluent — the idea behind Lyoprester, the cartridge that reconstitutes itself → — removes the error-prone mixing step.
• Male-fertility and hypogonadism therapy, where gonadotropin regimens run for months and stability directly shapes adherence.
• Global and low-resource access, where the cold chain is the binding constraint on who can be treated at all.
• Veterinary reproduction — gonadotropins (including equine chorionic gonadotropin) drive controlled breeding across agriculture, a large and cold-chain- sensitive market.
• Diagnostics. The same hCG that founded pregnancy testing anchors point-of-care assays whose reagents must stay active on a shelf, unrefrigerated.

These application fields are offered as reasoned directions, not claims — a map of where a preservation breakthrough for gonadotropins would matter most.

Frequently asked

Trending in the field

References & further reading

1. Gonadotropin — overview of the glycoprotein hormone family. Wikipedia.
2. Luteinizing hormone (LH). Wikipedia.
3. Follicle-stimulating hormone (FSH). Wikipedia.
4. Human chorionic gonadotropin (hCG). Wikipedia.
5. Gonadotropin-releasing hormone (GnRH) and pulsatile control. Wikipedia.
6. Follicle-stimulating hormone receptor (FSHR / LHCGR receptor biology). NCBI Gene: FSHR.
7. Bruno Lunenfeld — pioneer of clinical gonadotropin therapy. Wikipedia.
8. Menotropin (human menopausal gonadotropin / Pergonal). Wikipedia. See also the history of gonadotropin therapy on PubMed.
9. Aschheim-Zondek test — the first hCG-based pregnancy assay. Wikipedia.

Primary literature for the core claims

• Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annual Review of Biochemistry, 1981. PMID 6267989. Alpha/beta heterodimer structure and the role of glycosylation (sections 1 and 3).
• Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science, 1978 Nov 10. PMID 100883. Pulsatile GnRH drive of LH/FSH release (section 2; title spelling verbatim from PubMed).
• Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocrine Reviews, 2002 Apr. PMID 11943741. LHCGR receptor biology (section 3).
• Cole LA. Biological functions of hCG and hCG-related molecules. Reproductive Biology and Endocrinology, 2010 Aug 24. PMID 20735820. hCG biology (section 4).
• Lunenfeld B. Historical perspectives in gonadotrophin therapy. Human Reproduction Update, 2004 Nov-Dec. PMID 15388674. History of urinary gonadotropin therapy (section 7).